SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, ...
To diagnose heart conditions including heart attacks and heart rhythm disturbances, clinicians typically rely on 12-lead electrocardiograms (ECGs) -- complex arrangements of electrodes and wires ...
Vanessa is a lead writer at CNET, reviewing and writing about the latest smartwatches and fitness trackers. She joined the brand first as an on-camera reporter for CNET's Spanish-language site, then ...
Anginal symptoms/chest pain at rest that are associated with acute myocardial necrosis, as identified by elevated cardiac biomarkers (see Cardiac Enzymes Topic Review) without ST segment elevations on ...
A 52-year-old man is admitted to the hospital with complaints of increasing episodes of substernal chest discomfort. He is placed on telemetry. His dose of beta-blocker is increased and long-acting ...
Medical Device Network on MSN
HeartBeam commences pilot study of new 12-lead ECG patch
The study will enrol around 50 high-risk coronary artery disease patients whose resting ECGs show no signs of ischemia.
HeartBeam (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG ...
(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results